1. Generics Bulletin
  3. >>Strategy

Mallinckrodt Restructures Its Spinoff And Completes Management Team

 
• By Dave Wallace

Mallinckrodt has altered the composition of the Specialty Generics business that it plans to spin off by the end of this year, removing its Amitiza brand. The firm says it now has a “full management team in place” for the Specialty Generics unit after naming Eric Slusser as chief financial officer, to serve under president and CEO Matthew Harbaugh.

Spin
Mallinckrodt is aiming to reap rewards with the spinoff of its generics business • Source: Shutterstock

Mallinckrodt’s Amitiza (lubiprostone) brand will no longer form part of the Specialty Generics unit that the firm plans to spin off in the second half of 2019, under revised plans that have just been announced by the company.

“Given the strong, return-to-growth performance of the Specialty Generics business, it has been determined that the Amitiza product should remain with the Specialty Brands company,”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By Dave Wallace

During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”